Halozyme says royalty revenue should remain minimal through 2035 under new CMS rule
Halozyme projects zero to minimal impact to its royalty revenues through at least 2035 based on its analysis of CMS's final rule for the Medicare Drug Price Negotiation Program issued November 5, 2026. The company also says the rule does not affect its ability to enter new ENHANZE partnership agreements.
Primary source
Company press release (PR Newswire), November 6, 2026
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
Machine-summarized from the source above; not independently reported. How we use automation